We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Cell Biosciences Introduces Kits for Oncoprotein Analysis

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute
Cell Biosciences, Inc. has announced the launch of its first kits for the analysis of specific oncoproteins on the Firefly™ 3000 Protein Analysis System.

The new kits are optimized for characterization of proteins in the MEK and ERK families, which play critical roles in cancer cell survival and proliferation. Drug developers have targeted signaling via MEK and ERK with a number of kinase inhibitor anticancer drugs.

The Firefly 3000 system is an ultrasensitive nanofluidic immunoassay system designed to analyze extremely small biological samples. Traditional protein analysis techniques can require as many as 100,000 cells, which generally precludes protein analysis in precious clinical samples.

By using the analysis kits on the Firefly 3000 system, researchers can obtain detailed profiles of MEK and ERK signaling in as few as 25 cells. Subtle effects of kinase inhibitor drugs on MEK and ERK phosphorylation can be studied in cancer cells and solid tumor samples.

"We developed these oncoprotein analysis kits in response to strong interest from our cancer research customers," said Wilhelm Lachnit, Ph.D., Vice President of Research and Development. "They enable robust analysis of MEK and ERK phosphoprotein signaling, and provide a unique window into the specific actions of kinase inhibitor drugs in limited samples."